Logo image
Compounds targeting class II histone deacetylases do not cause panHDACI-associated impairment of megakaryocyte differentiation
Journal article   Open access   Peer reviewed

Compounds targeting class II histone deacetylases do not cause panHDACI-associated impairment of megakaryocyte differentiation

Damir Simic and Nianli Sang
Experimental hematology, v 72
01 Apr 2019
PMID: 30611870
url
https://doi.org/10.1016/j.exphem.2018.12.007View
Published, Version of Record (VoR)Open Access (Publisher-Specific) Open

Abstract

Hematology Life Sciences & Biomedicine Medicine, Research & Experimental Research & Experimental Medicine Science & Technology
Histone deacetylase inhibitors (HDACIs) have demonstrated effectiveness against lymphomas and myelomas in clinical practice. However, common to all currently approved broad-acting HDACIs (panHDACIs) is dose-limiting thrombocytopenia, which has prevented wider use in cancer therapy. Using CD34(+) hematopoietic stem cells (HSCs), we show that megakaryocyte (MK) cell maturation and differentiation are impaired by panHDACIs, correlating to clinical thrombocytopenia. Importantly, we demonstrate that inhibitors of class II histone deacetylases (HDACs), including LMK235 and tubacin at clinically relevant concentrations, do not affect MK maturation. Furthermore, we show that HDACI-induced impairment of MK differentiation is associated with reduction of protein levels of the transcription factor GATA-1, but not tubulin hyper-acetylation. Finally, we report that panHDACIs trigger a rapid loss of GATA-1 protein via a proteasome-dependent pathway. Our data support the notion that specifically targeting class II HDACs in cancer treatment is a potential strategy that would offer a safer alternative than current panHDACIs. (C) 2019 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Metrics

9 Record Views
2 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Hematology
Medicine, Research & Experimental
Logo image